Hydromorphon Stada

Hydromorphone, the active ingredient in Hydromorphon Stada, is an opioid analgesic presented as a oral tablet for oral use. It treats moderate to severe acute pain, post‑operative pain and cancer‑related pain in adult patients.

GNH USA supplies Hydromorphon Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydromorphon Stada is an opioid analgesic used to manage pain conditions across several clinical pathways.

- Moderate to severe acute pain: provides rapid analgesia for short‑term painful episodes. - Post‑operative pain: reduces discomfort following surgical procedures. - Cancer‑related pain: helps control persistent pain in oncology patients.

Hydromorphon Stada may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea - Constipation - Drowsiness - Dry mouth - Dizziness - Sweating

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Anaphylactic reaction - Adrenal insufficiency - Seizures - Dependence or addiction

When prescribing or dispensing Hydromorphon Stada, several safety considerations should be observed.

- Assess pain level: confirm that opioid therapy is appropriate for the patient. - Monitor respiratory function: watch for signs of depression, especially after dose initiation. - Evaluate renal and hepatic function: adjust therapy if impairment is present. - Avoid concomitant CNS depressants: limit use with benzodiazepines or alcohol. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Hydromorphon Stada can interact with other medicines, requiring careful review of a patient’s medication list.

Major Interactions (Avoid): - Concomitant use with other strong opioids: risk of additive respiratory depression. - Benzodiazepines or barbiturates: profound sedation and respiratory compromise. - Monoamine oxidase inhibitors (MAOIs): may precipitate severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): increase hydromorphone plasma levels. - CYP3A4 inducers (e.g., rifampin): reduce analgesic effectiveness. - Serotonergic agents (e.g., SSRIs): potential for serotonin syndrome.